Q3 EPS Estimates for Immix Biopharma Raised by HC Wainwright

Immix Biopharma, Inc. (NASDAQ:IMMX) – Analysts at HC Wainwright raised their Q3 2025 earnings estimates for Immix Biopharma in a report released on Wednesday, June 4th. HC Wainwright analyst R. Burns now anticipates that the company will earn ($0.16) per share for the quarter, up from their prior forecast of ($0.22). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Immix Biopharma’s current full-year earnings is ($0.87) per share. HC Wainwright also issued estimates for Immix Biopharma’s Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.62) EPS.

Immix Biopharma Price Performance

NASDAQ:IMMX opened at $2.37 on Friday. The firm has a market capitalization of $66.07 million, a P/E ratio of -2.79 and a beta of 0.31. The company’s fifty day moving average price is $1.91 and its 200-day moving average price is $1.95. Immix Biopharma has a 1-year low of $1.26 and a 1-year high of $3.00.

Immix Biopharma (NASDAQ:IMMX) last released its quarterly earnings data on Monday, March 24th. The company reported ($0.16) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.09.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Immix Biopharma stock. SBI Securities Co. Ltd. acquired a new stake in Immix Biopharma, Inc. (NASDAQ:IMMX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 17,500 shares of the company’s stock, valued at approximately $38,000. SBI Securities Co. Ltd. owned approximately 0.06% of Immix Biopharma as of its most recent filing with the Securities & Exchange Commission. 11.26% of the stock is currently owned by institutional investors and hedge funds.

About Immix Biopharma

Immix Biopharma, Inc, a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease.